Drug intelligence / Profile preview

Dextralink

Development stage: Unknown
Lead developer: Glaukos
Administration: Ophthalmic

Overview

Dextralink is a solution containing 0.1% riboflavin and 20% dextran, utilized in corneal cross-linking procedures. It functions as a photosensitizer, where riboflavin, upon activation by UV-A irradiation, induces the formation of cross-links within corneal collagen fibers. This process strengthens the corneal tissue, making it a treatment option for progressive corneal ectatic disorders such as pellucid marginal corneal degeneration and keratoconus.

Brand names: Dextralink
Other names: riboflavin/dextran ophthalmic solutionДекстралинк

Beyond the preview

Go deeper on Dextralink.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dextralink.

Explore the full profile